CA-CEPTON-TECHNOLOGIES
12.1.2021 12:02:29 CET | Business Wire | Press release
Cepton Technologies, Inc., a leading provider of state-of-the-art, intelligent, lidar-based solutions, has announced its path-breaking miniature lidar sensor – the Nova - priced at less than $100 for high volume automotive applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005035/en/
The Nova is a wide angle near-range lidar sensor intended to address major gaps in proximity detection of objects with current sensor technologies. Featuring best-in-class, high resolution 3D imaging with a high field of view (FOV) of 90-120° (H) and 60-90° (V), depending on configuration, Nova sets a worldwide benchmark with its unprecedented combination of compactness, FOV coverage and affordability.
Powered by Cepton’s patented and proven Micro Motion Technology (MMT® ), the non-rotational, mirrorless, and frictionless Nova lidar can be hidden all around a vehicle to provide a complete 360° view of its immediate surroundings. With a lidar target size of 3.5 cm (W) x 3.5 cm (H) x 7.5 cm (D), and weighing less than 350 g, the ultra-small Nova is an easily embeddable lidar sensor that not only enables optimal styling choices but demonstrates the scalability of MMT® to the smallest form factors.
Nova has an angular resolution of up to 0.3°, with a maximum range of up to 30 m and is therefore ideal for automotive Advanced Driver Assistance Systems (ADAS) and autonomous vehicle (AV) applications such as blind spot detection, small object detection, automated park assist and free space estimation around the vehicle. For vehicles, a multi-lidar architecture can be facilitated, thereby creating a virtual safety zone all around while minimizing disruption to vehicle design aesthetics.
Nova is ideally suited for accurate detection of objects in proximity, such as small children, on-road objects, road edges, stationary objects and more. With this level of capability and its ultra-compact design, Nova can not only support ADAS and AV applications but also autonomous ground vehicle (AGV) and smart industrial applications.
With lidar’s increasing presence in cars and trucks, Cepton has been innovating its technology to meet the stringent requirements from OEMs and Tier 1s while striving to advance lidar designs that enable easy integration in the next generation of automobiles. Nova is the latest representation of Cepton’s state-of-the-art lidar innovation, that encompasses the goal of automotive-grade reliability, low power (<3.5 W) and high performance, along with an elegant, minimalistic design that requires only small amounts of real estate in the vehicle body.
Nova’s modular design and easily accessible components make it highly manufacturable, with very low cost at high volume. Previously, Cepton was one of the first in the industry to announce a <$1,000 volume lidar price for high performance, long range lidar (Vista-X90). Consistent with that trend, Nova is the first high field of view, near-range lidar with a <$100 price point for high automotive volumes. This fulfils Cepton’s objective to bring to market scalable, mass-market lidar solutions that enable the automotive industry to substantially accelerate safety and autonomy innovations in the next generation of vehicles.
“The Nova is an industry-first, transformational lidar that fundamentally changes the game for near-field sensing,” said Cepton CEO Dr. Jun Pei. “Currently, consumer vehicles have been limited to technologies that cannot facilitate true Level 3 or Level 4 autonomy for the mass market. Radars, cameras and ultrasonic sensors suffer from high false positives and false negatives. Rotational lidars are not embeddable, making them impractical for consumer vehicles. Near-range flash lidars either lack the wide field of view or cannot match the power and size requirements to be discretely hidden all around the vehicle. The Nova represents path-breaking lidar innovation for the automotive industry in that it achieves a level of performance that is unmatched for such a small form factor.”
Nova is targeted for high volume production starting in 2023. Due to anticipated high demand for samples, Nova will only be available to select customers in 2021 through Cepton’s Early Access Program . If you would like to be part of this program or would like more details, please contact Mitch Hourtienne, Cepton Senior Director of Business Development at mitch.hourtienne@cepton.com .
To learn more about the Nova and Cepton’s automotive grade lidar capabilities, join Cepton at the upcoming digital CES 2021, from January 11th to 14th , via our virtual booth page (CES registration required). On Jan 12th , Cepton CMO, Dr. T. R. Ramachandran will join North American Lighting (NAL) for a virtual panel discussion on “Impact of Sensors on Mobility ” at 11 a.m. (PST) and present at an online NAL-hosted webinar “Lidar, What’s the Future? ” at 2 p.m. (PST). Watch the online sessions for free to learn more about how lidar is transforming the world and how Cepton’s smart lidar solutions are ideally suited for automotive and smart infrastructure applications.
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT® -based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom